Crossing the Goal Line; Bringing Ketamine Treatments to the Clinic
Tuesday, May 14, 2019, 2:00 pm EDT
The discovery and development of ketamine and now esketamine as rapidly acting antidepressants has been one of the major advances in the treatment of mood disorders in the past five decades. This Webinar will provide a brief history of the discovery and development process and will provide an overview of the various clinical trials completed to date. Discussion will focus on addressing clinically relevant questions related to the use of this exciting new treatment approach and the potential benefits this drug can offer to those with treatment-resistant depression.
Watch webinar recording:
Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.
Co-Director, Yale New Haven Hospital Interventional Psychiatry Service
Yale School of Medicine
Scientific Council Member (Joined 2015)
2014 Distinguished Investigator Grant
2007 Independent Investigator Grant
2001, 1999 Young Investigator Grant
Dr. Sanacora completed his Ph.D. in Physiology and Biophysics (1992) and his M.D. (1994) at the State University New York at Stony Brook. He then completed the Clinical Neuroscientist Training Program Residency and the Neuroimaging Scientist Training Program Fellowship at Yale. He is currently a Professor of Psychiatry at Yale and the Director of the Yale Depression Research Program. His work has concentrated largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders, and using this information to guide future treatment development. His basic science laboratory explores the effects of chronic stress on brain function, and examines the molecular, cellular and behavioral effects of newly developed treatment strategies. His clinical laboratory employs novel imaging methodologies to investigate the pathophysiology of neuropsychiatric disorders and is very active in clinical trial research.
Dr. Sanacora has received the Anna-Monkia Stiftung international award for the investigation of the biological substrate and functional disturbances of depression in 2009 and the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the American College of Neuropsychopharmacology in 2011.
Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy-nominated public television program “Healthy Minds,” and serves as host and executive producer of the series. The program, broadcast nationwide, is available online, and focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein served as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association from 2012 - 2023.
Dr. Borenstein is a Fellow of the New York Academy of Medicine and serves as the Chair of the Section of Psychiatry at the Academy. He also has served as the President of the New York State Psychiatric Association. Dr. Borenstein earned his undergraduate degree at Harvard and his medical degree at New York University.
